140 related articles for article (PubMed ID: 37560967)
1. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).
Perico N; Remuzzi G; Griffin MD; Cockwell P; Maxwell AP; Casiraghi F; Rubis N; Peracchi T; Villa A; Todeschini M; Carrara F; Magee BA; Ruggenenti PL; Rota S; Cappelletti L; McInerney V; Griffin TP; Islam MN; Introna M; Pedrini O; Golay J; Finnerty AA; Smythe J; Fibbe WE; Elliman SJ; O'Brien T;
J Am Soc Nephrol; 2023 Oct; 34(10):1733-1751. PubMed ID: 37560967
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study.
Packham DK; Fraser IR; Kerr PG; Segal KR
EBioMedicine; 2016 Oct; 12():263-269. PubMed ID: 27743903
[TBL] [Abstract][Full Text] [Related]
3. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
4. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane C
Trials; 2022 May; 23(1):401. PubMed ID: 35562778
[TBL] [Abstract][Full Text] [Related]
5. Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.
Gorman EA; Rynne J; Gardiner HJ; Rostron AJ; Bannard-Smith J; Bentley AM; Brealey D; Campbell C; Curley G; Clarke M; Dushianthan A; Hopkins P; Jackson C; Kefela K; Krasnodembskaya A; Laffey JG; McDowell C; McFarland M; McFerran J; McGuigan P; Perkins GD; Silversides J; Smythe J; Thompson J; Tunnicliffe WS; Welters IDM; Amado-Rodríguez L; Albaiceta G; Williams B; Shankar-Hari M; McAuley DF; O'Kane CM
Am J Respir Crit Care Med; 2023 Aug; 208(3):256-269. PubMed ID: 37154608
[No Abstract] [Full Text] [Related]
6. Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients.
Makhlough A; Shekarchian S; Moghadasali R; Einollahi B; Hosseini SE; Jaroughi N; Bolurieh T; Baharvand H; Aghdami N
Stem Cell Res Ther; 2017 May; 8(1):116. PubMed ID: 28535817
[TBL] [Abstract][Full Text] [Related]
7. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.
Farge D; Loisel S; Resche-Rigon M; Lansiaux P; Colmegna I; Langlais D; Charles C; Pugnet G; Maria ATJ; Chatelus E; Martin T; Hachulla E; Kheav VD; Lambert NC; Wang H; Michonneau D; Martinaud C; Sensebé L; Cras A; Tarte K
Lancet Rheumatol; 2022 Feb; 4(2):e91-e104. PubMed ID: 38288741
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up.
Makhlough A; Shekarchian S; Moghadasali R; Einollahi B; Dastgheib M; Janbabaee G; Hosseini SE; Falah N; Abbasi F; Baharvand H; Aghdami N
Cytotherapy; 2018 May; 20(5):660-669. PubMed ID: 29580865
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
10. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Krasnodembskaya A; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; McAuley DF; O'Kane CM
EClinicalMedicine; 2021 Nov; 41():101167. PubMed ID: 34746723
[TBL] [Abstract][Full Text] [Related]
13. Estimating glomerular filtration rate: Performance of the CKD-EPI equation over time in patients with type 2 diabetes.
Wood AJ; Churilov L; Perera N; Thomas D; Poon A; MacIsaac RJ; Jerums G; Ekinci EI
J Diabetes Complications; 2016; 30(1):49-54. PubMed ID: 26597601
[TBL] [Abstract][Full Text] [Related]
14. Hyperfiltration in Indigenous Australians with and without diabetes.
Ekinci EI; Hughes JT; Chatfield MD; Lawton PD; Jones GR; Ellis AG; Cass A; Thomas M; MacIsaac RJ; O'Dea K; Jerums G; Maple-Brown LJ
Nephrol Dial Transplant; 2015 Nov; 30(11):1877-84. PubMed ID: 26142395
[TBL] [Abstract][Full Text] [Related]
15. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
17. Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes.
Thomson HJ; Ekinci EI; Radcliffe NJ; Seah JM; MacIsaac RJ; Jerums G; Premaratne E
J Diabetes Complications; 2016 Mar; 30(2):256-61. PubMed ID: 26794645
[TBL] [Abstract][Full Text] [Related]
18. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
[TBL] [Abstract][Full Text] [Related]
19. Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats.
Quimby JM; Webb TL; Randall E; Marolf A; Valdes-Martinez A; Dow SW
J Feline Med Surg; 2016 Feb; 18(2):165-71. PubMed ID: 25784460
[TBL] [Abstract][Full Text] [Related]
20. The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function.
MacIsaac RJ; Ekinci EI; Premaratne E; Lu ZX; Seah JM; Li Y; Boston R; Ward GM; Jerums G
BMC Nephrol; 2015 Dec; 16():198. PubMed ID: 26630928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
